Comparative Efficacy of BTK Inhibitors in Treatment‑Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‑Analysis
Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL).
Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment‑naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta‑analysis was intended to evaluate their efficacy, addressing critical gaps in clinical decision‑making. ...
The claim highlights the therapeutic relevance of BTK inhibitors in mantle cell lymphoma, underscoring their role as a frontline or salvage option and framing the comparative evaluation of different agents within the same drug class.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa